Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Consulting agrmnt
Director departure
Appointed director
CC transcript
Notes underwriting agrmnt
Inv. presentation
|
|
Sarepta Therapeutics, Inc. (SRPT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/15/2023 |
4
| Chambers Michael Andrew (Director) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Bought 5,947 shares
@ $109.19, valued at
$649.4k
Bought 4,032 shares
@ $109.89, valued at
$443.1k
|
|
| 08/14/2023 |
4
| Chambers Michael Andrew (Director) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Bought 23,686 shares
@ $108.05, valued at
$2.6M
|
|
| 08/11/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/08/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/04/2023 |
4
| Arif Bilal (Chief Tech Ops Officer) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 307 shares
@ $136.66, valued at
$42k
|
|
| 03/10/2023 |
4
| Rodino-Klapac Louise (Head of R&D, CSO) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 912 shares
@ $153.19, valued at
$139.7k
|
|
| 03/10/2023 |
4
| Estepan Ian Michael (CFO) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 744 shares
@ $153.19, valued at
$114k
|
|
| 03/10/2023 |
4
| Brown Ryan Edward (SVP, General Counsel) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 635 shares
@ $153.19, valued at
$97.3k
|
|
| 03/10/2023 |
4
| Arif Bilal (Chief Tech Ops Officer) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 314 shares
@ $153.19, valued at
$48.1k
|
|
| 03/08/2023 |
4
| Wigzell Hans Lennart Rudolf (Director) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Granted 1,523 shares
@ $0
Granted 3,257 options to buy
@ $155.99, valued at
$508.1k
|
|
| 03/08/2023 |
4
| Arif Bilal (Chief Tech Ops Officer) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 186 shares
@ $157.21, valued at
$29.2k
Paid exercise price by delivering 154 shares
@ $157.21, valued at
$24.2k
Granted 4,500 shares
@ $0
Granted 27,000 options to buy
@ $155.99, valued at
$4.2M
|
|
| 03/08/2023 |
4
| BEHRENS M KATHLEEN (Director) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Granted 1,523 shares
@ $0
Granted 3,257 options to buy
@ $155.99, valued at
$508.1k
|
|
| 03/08/2023 |
4
| Estepan Ian Michael (CFO) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 1,370 shares
@ $157.21, valued at
$215.4k
Granted 4,500 shares
@ $0
Granted 27,000 options to buy
@ $155.99, valued at
$4.2M
|
|
| 03/08/2023 |
4
| Barry Richard (Director) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Granted 1,523 shares
@ $0
Granted 3,257 options to buy
@ $155.99, valued at
$508.1k
|
|
| 03/08/2023 |
4
| Rodino-Klapac Louise (Head of R&D, CSO) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 1,134 shares
@ $157.21, valued at
$178.3k
Granted 4,500 shares
@ $0
Granted 27,000 options to buy
@ $155.99, valued at
$4.2M
|
|
| 03/08/2023 |
4
| Brown Ryan Edward (SVP, General Counsel) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 1,154 shares
@ $157.21, valued at
$181.4k
Paid exercise price by delivering 171 shares
@ $157.21, valued at
$26.9k
Granted 4,500 shares
@ $0
Granted 27,000 options to buy
@ $155.99, valued at
$4.2M
|
|
| 03/08/2023 |
4
| Chambers Michael Andrew (Director) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Granted 1,523 shares
@ $0
Granted 3,257 options to buy
@ $155.99, valued at
$508.1k
|
|
| 03/08/2023 |
4
| Boor Kathryn Jean (Director) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Granted 1,523 shares
@ $0
Granted 3,257 options to buy
@ $155.99, valued at
$508.1k
|
|
| 03/08/2023 |
4
| Nicaise Claude (Director) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Granted 1,523 shares
@ $0
Granted 3,257 options to buy
@ $155.99, valued at
$508.1k
|
|
| 03/08/2023 |
4
| Mayo Stephen (Director) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Granted 1,523 shares
@ $0
Granted 3,257 options to buy
@ $155.99, valued at
$508.1k
|
|
| 03/03/2023 |
4
| Arif Bilal (Chief Tech Ops Officer) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 80 shares
@ $147.57, valued at
$11.8k
Paid exercise price by delivering 172 shares
@ $147.57, valued at
$25.4k
|
|
| 03/03/2023 |
4
| Brown Ryan Edward (SVP, General Counsel) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 196 shares
@ $147.57, valued at
$28.9k
|
|
| 03/03/2023 |
4
| Estepan Ian Michael (CFO) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 378 shares
@ $147.57, valued at
$55.8k
|
|
| 03/03/2023 |
4
| Rodino-Klapac Louise (Head of R&D, CSO) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 522 shares
@ $147.57, valued at
$77k
|
|
| 01/04/2023 |
4
| Arif Bilal (Chief Tech Ops Officer) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Granted 30,000 options to buy
@ $129.58, valued at
$3.9M
|
|
| 01/04/2023 |
3
| Arif Bilal (Chief Tech Ops Officer) has filed a Form 3 on Sarepta Therapeutics, Inc. |
| 12/21/2022 |
4
| BEHRENS M KATHLEEN (Director) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Exercised 20,000 options to buy
@ $34.92, valued at
$698.4k
|
|
| 11/21/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/21/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/15/2022 |
4
| Chambers Michael Andrew (Director) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Bought 20,744 shares
@ $103.87, valued at
$2.2M
Bought 30,106 shares
@ $104.67, valued at
$3.2M
Bought 6,250 shares
@ $105.16, valued at
$657.3k
|
|
| 09/14/2022 |
4
| Chambers Michael Andrew (Director) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Granted options to buy
@ $141.97, valued at
$0 |
|
| 08/22/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/06/2022 |
4
| Boor Kathryn Jean (Director) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Granted 4,908 shares
@ $0
Granted 8,329 options to buy
@ $72.58, valued at
$604.5k
|
|
| 06/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|
|